Albany Law School's Health Law Clinic successfully appealed a crucial insurance denial for a client with terminal, irreversible, primary brain cancer.
On September 6, 2007, the Clinic submitted the appeal for insurance coverage of the cutting-edge treatment Avastin/CPT-11-known generically as Bevacizumab and Irinotecan. Six days later, Empire Blue Cross approved the treatment, finding it "medically necessary," and will provide coverage for one year of life-prolonging treatment.
The appeal included a cover letter requesting an expedited appeal, the client's affidavit, an affidavit from the client's physician and research studies demonstrating the proven benefits of this treatment.
On December 14, 2007, the
New York Law Journal featured an article about the case.
Read the article. [PDF]